Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
June 2014, Vol 5, No 5
June 2014, Vol 5, No 5
Nationwide Adoption of LDCT Screening Will Detect More Early-Stage Lung Cancer, but at Substantial Economic Cost
By
Phoebe Starr
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The US Preventive Services Task Force (USPSTF) recommends annual low-dose computed tomography (LDCT) lung cancer screening for patients at high risk. What would it mean in terms of cost to society if those recommendations were implemented in the Medicare population?
Read Article
Breakthrough Therapy Designation Program: Reviewing the First-Year Experience
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The US Food and Drug Administration (FDA) introduced the concept of a breakthrough therapy designation in 2012 to help expedite patient access to new therapies for the treatment of serious or life-threatening diseases.
Read Article
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
By
Wayne Kuznar
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Read Article
Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy
By
Wayne Kuznar
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Read Article
Study Identifies Troubling Trends in NSCLC Trials
In the Literature
June 2014, Vol 5, No 5
Changes in the design and interpretation of phase 3 trials for advanced non–small-cell lung cancer (NSCLC) have begun to emerge regarding statistical power, sample size, and the primary end points used. In a new study, researchers explored how the design and interpretation of these trials has changed over the past 3 decades.
Read Article
Panitumumab and Cetuximab Show Comparable Survival Benefit in Patients with Metastatic Colorectal Cancer
In the Literature
June 2014, Vol 5, No 5
Panitumumab (Vectibix) proved noninferior to cetuximab (Erbitux) in overall survival (OS) in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC), according to the results of ASPECT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab).
Read Article
Genetic Testing to Select Targeted Therapies Increases Survival in Lung Cancer
In the Literature
June 2014, Vol 5, No 5
The identification of oncogenic drivers has helped transform the care of patients with adenocarcinoma, the most common type of lung cancer diagnosed in 130,000 patients in the United States and 1 million persons worldwide annually.
Read Article
Veliparib, a PARP Inhibitor, Active in Recurrent BRCA-Positive Ovarian Cancer
By
Charles Bankhead
Ovarian Cancer
June 2014, Vol 5, No 5
Tampa, FL—The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib demonstrated activity in relapsed and/or refractory BRCA-mutated ovarian cancer, according to the results of a phase 2 clinical trial reported at the 2014 Society of Gynecologic Oncology meeting.
Read Article
Worksite Pharmacies Can Enhance Overall Drug Management of Patients with Cancer
By
Wayne Kuznar
June 2014, Vol 5, No 5
Los Angeles, CA—Worksite pharmacies have unique advantages over local pharmacies in caring for employees with cancer.
Read Article
Worksite Health Centers Can Help Employees Manage Cancer
By
Wayne Kuznar
June 2014, Vol 5, No 5
Los Angeles, CA—Worksite health centers can improve the quality and effectiveness of cancer treatment for employees while reducing costs for their employers.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma